

Agnieszka E. Laudy,<sup>a</sup> Rosa Moo-Puc,<sup>b</sup> Roberto Cedillo-Rivera,<sup>b</sup>  
Zygmunt Kazimierzczuk,<sup>c</sup> and Andrzej Orzeszko<sup>c,d,\*</sup>

<sup>a</sup>Department of Pharmaceutical Microbiology, Medical University of Warsaw,  
Warsaw 00-007, Poland

<sup>b</sup>Unidad de Investigación Médica Yucatán, Unidad Médica de Alta Especialidad,  
Instituto Mexicano del Seguro Social, Mérida, Yuc., México

<sup>c</sup>Institute of Chemistry, Warsaw University of Life Sciences, Warsaw 02-787, Poland


<sup>d</sup>Military University of Technology, Warsaw 00-908, Poland

\*E-mail: Andrzej\_Orzeszko@sggw.pl

Received February 5, 2011

DOI 10.1002/jhet.936

Published online 26 October 2012 in Wiley Online Library (wileyonlinelibrary.com).



A series of new polyhalogenated benzimidazoles has been synthesized and their antibacterial and antiprotozoal activity was evaluated. Several of new substituted halogenobenzimidazoles and their 2'-deoxynucleosides showed noteworthy antiprotozoal toxicity particularly against *Giardia lamblia*. The most potent agents against bacteria and fungi were 4,5,6,7-tetrachlorobenzimidazoles with polyfluoroalkyl chain at position 2 of the heterocycle.

*J. Heterocyclic Chem.*, **49**, 1059 (2012).

## INTRODUCTION


Halogenated benzimidazoles and their derivatives have raised special interest because of their diversified biological activity. For example, tetrabromobenzimidazoles and tetraiodobenzimidazoles are known as very strong inhibitors of antiapoptotic protein kinase CK2 [1–3]. Among antiviral agents, benzimidazole nucleosides and acyclo-nucleosides have also received much attention. The 5,6-dichloro-1-(β-D-ribofuranosyl)-benzimidazole (DRB) and its derivatives (TCRB and BDCRB) were found to show activity against RNA and DNA viruses [4, 5]. Also some benzimidazole L-ribonucleosides, particularly 5,6-dichloro-2-isopropylamino-1-(β-L-ribofuranosyl)-benzimidazole (maribavir) inhibit replication of human cytomegalovirus and have favorable safety profiles in animal species [6]. Benzimidazole system is present in numerous antiparasitic, fungicidal, anthelmintic, and anti-inflammatory drugs [7–9]. Substituted 2-trifluorobenzimidazoles are potent decouplers of oxidative phosphorylation in mitochondria. These compounds also inhibit photosynthesis and therefore exhibit appreciable herbicidal activity [10].

Their antibacterial, antifungal, and antiprotozoal activity has been reported [11–13].

These findings have inspired us to widen the list of halogeno-substituted benzimidazoles and to test the new derivatives against selected Gram-positive and Gram-negative bacteria and protozoa. In addition to previously reported compounds, we have synthesized several new halogenobenzimidazole derivatives as well as two 2'-deoxyribonucleosides. Despite a pilot-study character of our investigation, we were able to indicate the direction which can provide new effective antimicrobial agents of wide activity spectrum. The emergence of resistance to the major classes of antibacterial agents is recognized as a serious health concern. The search for antimicrobial agents with new mode of action will always remain an important task.

## RESULTS AND DISCUSSION


The synthesis of several newly modified benzimidazoles carrying chloro- and bromo-substituents on the benzene part of heterocycle as well as other substituents on C-2 and N-1 position constituted the chemical part of this

**Scheme 1.** Reagents and conditions: (i) HCl/HNO<sub>3</sub> (aqua regia).


study. Additionally, two 2'-deoxyribo-nucleosides of 4,5,6,7-tetrachloro- and 5,6-dichloro-4,7-diiodobenzimidazoles (**10a,b**) were obtained according to "sodium salt procedure" [14] (Schemes 1–3).

Benzimidazole ring system endures even hard reaction conditions. The full chlorination of benzimidazole in the benzene part of molecule was achieved by action of "aqua

regia" [15] or in the case of 2-trifluorobenzimidazole by action of chlorine at elevated temperature [16]. We have applied successfully the first procedure for chlorination of 2-perfluoroalkylbenzimidazoles **1a–d** with good or moderate yields to obtain respective products **2a–d** (Scheme 1). Additionally, the two previously obtained 4,5,6,7-tetraiodo-2-perfluoroalkyl benzimidazoles **2e** and **2f** were subjected to antimicrobial testing [3]. 4,5,6,7-Tetrachlorobenzimidazole **3a** was substituted in position N-1 with ethyl bromoacetate to give the respective ester **4a**. This ester was transformed to acid **5** by alkaline hydrolysis. The hydrazide **6** and amides derived from piperidine, morpholine, and methylpiperazine **7a–c** were obtained by reaction of **4a** with hydrazine or prolonged heating with piperidine, morpholine, or *N*-methylpiperazine, respectively. A similar procedure was adapted for a tetrabromoester **4b** in the synthesis of its methylpiperazinyl amide **7d** (Scheme 2). Because of the moderate biological activity of **7d**, we gave up the synthesis of other similarly modified tetrabromobenzimidazoles. Compounds **3b** and **4b** used here as starting materials for further synthesis and biological investigations have been described previously [3, 17]. Additionally, the synthesis of two 2'-deoxyribonucleosides **10a** and **10b** by condensation of sodium salts of 4,5,6,7-tetrachlorobenzimidazole **3a** and 5,6-

**Scheme 2.** Reagents and conditions: (i) BrCH<sub>2</sub>COOEt, K<sub>2</sub>CO<sub>3</sub>, acetone, reflux; (ii) NaOH/ETOH; (iii) hydrazine/EtOH; (vi) NH(CH<sub>2</sub>)<sub>4</sub>X, reflux.

**Scheme 3.** Reagents and conditions: (i) 2-deoxy-3,5-bis-*O*-(4-methylbenzoyl)- $\beta$ -D-erythro-pentafuranosyl chloride, NaH, CH<sub>3</sub>CN, stirring; (ii) MeONa/MeOH.



dichloro-4,7-diiodobenzimidazole **8** with 3,5-di-*O*-(*p*-toluoyl)- $\alpha$ -D-ribofuranosyl chloride was carried out. This stereoselective reaction provides almost exclusively  $\beta$ -anomers. Removal of *p*-toluoyl groups from **9a** and **9b** was realized by treating of blocked nucleosides with methanolic sodium methoxylate (Scheme 3).

The halogenated benzimidazoles were screened for their antiprotozoal activity against *Entamoeba histolytica*, *Trichomonas vaginalis*, and *Giardia lamblia* (Table 1). The results revealed that some of tested compounds are endowed with an appreciable antiprotozoal activity. The most potent agents against *E. histolytica* were **2a**, **7a**, and

**7c**. Tetrachlorobenzimidazoles with longer polyfluoroalkyl chain **2b–d** showed the best toxicity toward *T. vaginalis*, whereas its 2-trifluoromethyl analogue (**2a**) has distinctly lower IC<sub>50</sub> value. Four compounds: amides **7a** and **7b** and deoxynucleosides **10a** and **10b** exhibited very potent anti-giardial activity, comparable but higher than control compounds: albendazole and metronidazole. In all tests, tetraiodinated (**2e** and **2f**) or tetrabrominated benzimidazole derivatives (**7d**) were less toxic than their tetrachloro congeners (see also results in [13]).

The majority of the halogenobenzimidazoles investigated here were active against Gram-positive bacteria (Table 2).

**Table 1**

*In vitro* susceptibility of *Entamoeba histolytica*, *Trichomonas vaginalis*, and *Giardia lamblia* to novel polyhalogenobenzimidazoles.

Compound tested	<i>Entamoeba histolytica</i>		<i>Trichomonas vaginalis</i>		<i>Giardia lamblia</i>	
	IC <sub>50</sub> [ $\mu$ g/ml]	95% Confidence limits	IC <sub>50</sub> [ $\mu$ g/ml]	95% Confidence limits	IC <sub>50</sub> [ $\mu$ g/ml]	95% Confidence limits
<b>2a</b>	0.29	0.289–0.292	5.35	5.33–5.38	8.6	8.62–8.77
<b>2b</b>	2.43	2.42–2.44	0.37	0.375–0.378	n.a	
<b>2c</b>	5.05	5.03–5.08	0.40	0.402–0.405	11.5	11.4–11.7
<b>2d</b>	1.90	1.89–1.91	0.22	0.218–0.225	21.3	20.4–22.3
<b>2e</b>	2.60	2.58–2.61	17	16.7–17.4	8.25	8.20–8.31
<b>2f</b>	151	149–152	149	143–156	4.92	4.89–4.95
<b>3a</b>	1.655	1.648–1.662	0.75	0.745–0.754	0.027	0.026–0.028
<b>5</b>	2.279	2.265–2.292	117.8	114.7–121.3	0.188	0.189–0.186
<b>6</b>	3.07	3.05–3.09	5.33	5.28–5.39	13.06	12.94–13.18
<b>7a</b>	1.208	1.203–1.214	19.62	19.34–19.91	0.007	0.0069–0.0071
<b>7b</b>	1.449	1.441–1.457	134.8	130.4–139.5	0.002	0.0018–0.0021
<b>7c</b>	0.18	0.178–0.180	1.72	170–173	9.16	9.06–9.27
<b>7d</b>	0.48	0.478–0.483	20.8	20.5–20.8	46.5	45.7–47.4
<b>10a</b>	1.124	1.119–1.129	0.993	0.989–0.997	0.004	0.0039–0.0041
<b>10b</b>	1.643	1.633–1.653	0.678	0.674–0.682	0.029	0.029–0.030
Albendazole	15.0	10.0–20.0	0.422	0.419–0.425	0.010	0.008–0.012
Metronidazole	0.060	0.029–0.103	0.037	0.037–0.037	0.210	0.150–0.270

n.a, no activity.

IC<sub>50</sub>, the concentration required to inhibit growth by 50%.



**Table 3**  
Activity of selected benzimidazoles against Gram-negative bacteria and fungi.

Bacterium	Diameter of growth inhibition area, mm; (MIC [ $\mu\text{g/mL}$ ])					Yeast strain	Diameter of growth inhibition area, mm; (MIC [ $\mu\text{g/mL}$ ])				
	2a	2b	2c	2d	N <sup>f</sup>		2a	2b	2c	2d	Fluconazol <sup>b</sup>
<i>Escherichia coli</i>	ATCC 25922	16 (200)	15 (200)	(-) (200)	24 (6.25)	<i>Candida albicans</i> ATCC 90028	12 (100)	(-) (>400)	(-) (>400)	(-) (>400)	43 (2)
<i>Escherichia coli</i>	NCTC 8196	17 (200)	16 (200)	(-) (100)	24 (6.25)	<i>Candida parapsilosis</i> ATCC 22019	(-) (50)	(-) (50)	(-) (>400)	(-) (>400)	32 (2)
<i>Klebsiella pneumoniae</i>	ATCC 13883	12 (400)	12 (400)	(-) (400)	23 (25)	<i>Candida tropicalis</i> IBA 171	25 (12.5)	18 (25)	(-) (>400)	(-) (>400)	39 (0.38)
<i>Proteus vulgaris</i>	NCTC 4635	34 (12.5)	35 (25)	15 (50)	17 (100)	<i>Candida krusei</i> IBA 161	20 (50)	15 (50)	(-) (>400)	(-) (>400)	16 (>256)
<i>Pseudomonas aeruginosa</i>	NCTC 6749	13 (200)	11 (200)	(-) (200)	(-) (>400)	<i>Candida quilliermondii</i> IBA 155	33 (<3.125)	28 (<3.125)	15 (<3.125)	12 (<3.125)	40 (0.75)
<i>Pseudomonas aeruginosa</i>	ATCC 27853	12 (400)	10 (>400)	(-) (400)	(-) (>400)	<i>Saccharomyces cerevisiae</i> IBA 198	14 (50)	25 (25)	(-) (>400)	(-) (>400)	12 (>256)
<i>Stenotrophomonas maltophilia</i>	ATCC 13637	18 (200)	18 (100)	(-) (100)	(-) (>400)	-	-	-	-	-	-
<i>Burkholderia cepacia</i>	ATCC 25416	25 (100)	21 (100)	(-) (50)	(-) (>400)	-	-	-	-	-	-
<i>Acinetobacter baumannii</i>	ATCC 19606	20 (200)	17 (200)	(-) (200)	14 (200)	-	-	-	-	-	-
<i>Bordetella bronchiseptica</i>	ATCC 4617	28 (50)	25 (50)	19 (25)	(-) (>400)	-	-	-	-	-	-

<sup>a</sup>Nf, nitrofurantoin, reference compound, 300  $\mu\text{g}$  per disk (Mast Diagnostics, UK).

<sup>b</sup>Fluconazole, reference compound, filter paper disks used for disk-diffusion method contained 25  $\mu\text{g}$  of fluconazole per disk, whereas Etest gradient strips (AB Biodisk) were used for the determination of fluconazole MICs.



acetone (2 × 40 mL). The filtrate was evaporated to dryness, and the residue crystallized from ethanol to give white needles. Yield: 4.2 g, (81%), mp 167–168°C; <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>): δ 1.21 (t, *J* = 7.1 Hz, 3H), 4.20 (q, *J* = 7.1 Hz, 2H), 5.46 (s, 2H), 8.47 (s, 1H). *Anal.* Calcd. for C<sub>11</sub>H<sub>8</sub>Cl<sub>4</sub>N<sub>2</sub>O<sub>2</sub> (342.01): C, 38.63; H 2.36; N, 8.19. Found: C, 38.51; H, 2.39; N, 8.08.

**(4,5,6,7-Tetrachlorobenzimidazol-1-yl)acetic acid (5).** The mixture containing **4a** (680 mg, 2 mmol), ethanol (15 mL), water (10 mL) and NaOH (240 mg, 6 mmol) was stirred at room temp. for 3 h. The suspension became clear after this time. Next, the mixture was brought to reflux for 10 min. The solution was acidified to pH 2–3 with diluted aqueous HCl and left to crystallization. The amorphous white powder was obtained. Yield: 610 mg (97 %), mp 303–306°C (from ethanol-water); <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>): δ 5.35 (s, 1H), 8.47 (s, 1H), 13.5 (s, 1H). uv (MeOH): λ (ε) nm. *Anal.* Calcd. for C<sub>9</sub>H<sub>4</sub>Cl<sub>4</sub>N<sub>2</sub>O<sub>2</sub> (313.96): C, 34.43; H 1.28; N, 8.92. Found: C, 34.50; H, 1.37; N, 8.81.

**(4,5,6,7-Tetrachlorobenzimidazol-1-yl)acetic acid hydrazide (6).** To the solution of **4a** (1.02 g, 3 mmol) in ethanol (30 mL) hydrazine monohydrate (98%, 1.2 g, 24 mmol) was added. The mixture was stirred and refluxed for 3h. Next, the water (15 mL) was added and the mixture was left to crystallization. The white precipitate was formed. Yield: 870 mg, (88%), mp > 300°C (with decomp.). For analysis, a small amount of (**6**) was crystallized from ethanol. <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>): δ 4.35 (bs, 2H), 5.18 (s, 2H), 8.45 (s, 1H), 9.42 (s, 1H). uv (MeOH): λ (ε) 230 (16,600), 264 (8900), 271 (9900), 290 (sh, 3300), 300 (3100) nm. *Anal.* Calcd. for C<sub>9</sub>H<sub>4</sub>Cl<sub>4</sub>N<sub>4</sub>O (327.99): C, 32.96; H, 1.84; N, 17.08. Found: C, 32.85; H, 1.84; N, 17.08.

**1-(Piperidin-1-yl)-2-(4,5,6,7-tetrachlorobenzimidazol-1-yl)-etanone (7a).** The mixture of **4a** (340 mg, 1 mmol) and piperidine (510 mg, 6 mmol) was stirred and refluxed for 36 h. Next, the mixture was evaporated to oil. The residue was crystallized twice from toluene-ethanol. Yield: 295 mg, (77%), mp 240–242°C; <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>): δ 1.09 (t, *J* = 5.3 Hz, 4H) and 2.87 (q, *J* = 7.2 Hz, 4H), 4.94 (s, 2H), 8.38 (s, 1H). uv (MeOH): λ (ε) 227 (22,700), 273 (8900), 301 (3400) nm. *Anal.* Calcd. for C<sub>14</sub>H<sub>13</sub>Cl<sub>4</sub>N<sub>3</sub>O (381.09): C, 44.12; H, 3.44; N, 11.03. Found: C, 44.21; H, 3.54; N, 10.91.

**1-(Morpholin-4-yl)-2-(4,5,6,7-tetrachlorobenzimidazol-1-yl)-etanone (7b).** Analogously as for **7a**. Yield: 195 mg, (51%), mp 221–223°C; <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>): δ 2.95 (t, *J* = 4.8 Hz, 4H), 3.68 (t, *J* = 4.8 Hz, 4H), 4.93 (s, 2H), 8.40 (s, 1H); uv (MeOH): λ (ε) 226 (23,400), 272 (8800), 300 (3300) nm. *Anal.* Calcd. for C<sub>13</sub>H<sub>11</sub>Cl<sub>4</sub>N<sub>3</sub>O<sub>2</sub> (383.06): C, 40.76; H, 2.89; N, 10.97. Found: C, 40.67; H, 2.99; N, 10.85.

**1-(4-Methylpiperazin-1-yl)-2-(4,5,6,7-tetrachlorobenzimidazol-1-yl)-etanone (7c).** The mixture of ester **4a** (380 mg, 1.1 mmol) and *N*-methylpiperazine (1.2 g, 12 mmol) in methoxyethanol (20 mL) was stirred and heated at 110°C (bath temp.) for 2 days. The solvent was removed and the brown residue was chromatographed on silica gel column (2.5 × 8 cm) with CHCl<sub>3</sub> (100 mL), CHCl<sub>3</sub>-MeOH (8:2, v/v) (100 mL) and CHCl<sub>3</sub>-MeOH-Et<sub>3</sub>N (80:18:2, v/v/v). The product containing fractions were evaporated and the residue crystallized from toluene-EtOH to give white cottonlike powder. Yield: 230 mg, (53%), mp 229–232°C; <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>): δ 2.18 (s, 3H), 2.42 (t, *J* = 5.8 Hz, 4H), 2.94 (t, *J* = 5.0 Hz, 4H), 4.89 (s, 2H), 8.37 (s, 1H). uv (MeOH): λ (ε) 228 (24,000), 272 (8900), 301 (3300). *Anal.* Calcd. for C<sub>14</sub>H<sub>14</sub>Cl<sub>4</sub>N<sub>4</sub>O (396.11): C, 42.45; H, 3.56; N, 14.14. Found: C, 42.56, H, 3.63, N, 14.06.

**1-(4-Methylpiperazin-1-yl)-2-(4,5,6,7-tetrabromobenzimidazol-1-yl)-etanone (7d).** As described above for **7c** from **4b** [2] and *N*-methylpiperazine. Yield: 315 mg (50%), mp 219–221°C; <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>): δ 2.18 (s, 3H), 2.41 (t, *J* = 5.1 Hz, 4H), 2.93 (t, *J* = 5.2 Hz, 4H), 4.90 (s, 2H), 8.35 (s, 1H). uv (MeOH): λ (ε) 230 (35,000), 750 (sh, 9400) 275 (9600), 302.5 (3600). *Anal.* Calcd. for C<sub>14</sub>H<sub>14</sub>Br<sub>4</sub>N<sub>4</sub>O (573.91): C, 29.30; H, 2.46; N, 9.76. Found: C, 29.36, H, 2.54, N, 9.64.

**1-[2-Deoxy-3,5-di-*O*-(4-methylbenzoyl)-β-*D*-erythro-pentafuranosyl]-4,5,6,7-tetrachloro-benzimidazole (9a).** To the suspension of **3a** (1.02 g, 4 mmol) in dry acetonitrile (70 mL), sodium hydride (200 mg, 5 mmol, 60% in oil) was added portionwise. The mixture was stirred and refluxed for 10 min. After cooling 2-deoxy-3,5-bis-*O*-(4-methylbenzoyl)-β-*D*-erythro-pentafuranosyl chloride [18] (1.55 g, 4 mmol) was added in portions. The mixture was stirred for 20 min at r.t. Next, methylene chloride (70 mL) was added and the mixture filtered through Cellite. The solvents were evaporated and the residue was chromatographed on silica gel column (2.5 × 12 cm) with toluene-acetone (95:5, v/v) as eluent. The product containing fractions were evaporated and the residue crystallized from methanol to give white needles. Yield: 1.09 g, (45%), mp 191–192°C; <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>): δ 2.37 (s, 3H), 2.40 (s, 3H), 2.96 (m, 1H), 3.07 (m, 1H), 4.52 (m, 2H), 4.58 (m, 1H), 5.72 (m, 1H), 7.01 (t, *J* = 6.4 Hz, 1H), 7.30–8.0 (4d, arom. H, 8H), 8.82 (s, 1H). *Anal.* Calcd. for C<sub>28</sub>H<sub>22</sub>Cl<sub>4</sub>N<sub>2</sub>O<sub>5</sub> (608.31): C, 55.29; H, 3.65; N, 4.61. Found: C, 55.25; H, 3.60; N, 4.52.

**1-[2-Deoxy-3,5-di-*O*-(4-methylbenzoyl)-β-*D*-erythro-pentafuranosyl]-5,6-dichloro-4,7-diiodobenzimidazole (9b).** As described for **9a** from **8** [3] instead of **3a**. Yield: 1.64 mg (52%), mp 194–196°C; <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>): δ 2.37 (s, 3H), 2.40 (s, 3H), 2.96 (m, 1H), 3.09(m, 1H), 4.56 (m, 2H), 4.60 (m, 1H), 5.70 (m, 1H), 7.37 (t, *J* = 7.9 Hz, 1H), 7.30–8.0 (4d, arom.H, 8H), 8.81 (s, 1H). *Anal.* Calcd. for C<sub>28</sub>H<sub>22</sub>Cl<sub>2</sub>I<sub>2</sub>N<sub>2</sub>O<sub>5</sub> (791.21): C, 42.51; H, 2.80; N, 3.54. Found: C, 42.43; H, 2.86; N, 3.45.

**1-(2-Deoxy-β-*D*-erythro-pentafuranosyl)-4,5,6,7-tetrachlorobenzimidazole (10a).** The mixture of **9a** (1.6 g, 2.63 mmol) and methanolic sodium methanolate (50 mL, 0.1M) was stirred and refluxed for 15 min. Methanol was evaporated and the residue purified by flash chromatography on silica gel (2.5 × 10 cm) using chloroform as eluent. The product containing fractions were evaporated and the residue crystallized from methanol water to give colorless needles. Yield: 685 mg, (70%), mp 141–144°C; <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>): δ 2.46 (m, 1H), 2.58 (m, 1H), 3.65 (2m, 2H), 3.89 (q, *J* = 3.9 Hz, 1H), 4.47 (m, 1H), 5.04 (t, *J* = 5.2 Hz, 1H), 5.36 (d, *J* = 4.5 Hz, 1H), 6.85 (t, *J* = 5.9 Hz, 1H), 8.88 (s, 1H). uv (MeOH): λ (ε) 225 (22,400), 270 (9200), 298 (3100). *Anal.* Calcd. for C<sub>12</sub>H<sub>10</sub>Cl<sub>4</sub>N<sub>2</sub>O<sub>3</sub> (372.04): C, 38.74; H, 2.71; N, 7.53. Found: C, 38.66; H, 2.77; N, 7.47.

**1-(2-Deoxy-β-*D*-erythro-pentafuranosyl)-5,6-dichloro-4,7-diiodobenzimidazole (10b).** As described for **10a** from **9b**. Yield: 695 mg, (68%), mp 200°C; <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>): δ 2.46 (m, 1H), 2.55 (m, 1H), 3.60 (2m, 2H), 3.89 (q, *J* = 3.8 Hz, 1H), 4.37 (q, *J* = 4.7 Hz, 1H), 5.07 (bs, 1H), 5.37 (bs, 1H), 7.23 (t, *J* = 6.1 Hz, 1H), 8.87 (s, 1H). uv (MeOH): λ (ε) 230 (27,000), 279 (14,000), 305 (sh, 6100). *Anal.* Calcd. for C<sub>12</sub>H<sub>10</sub>Cl<sub>2</sub>I<sub>2</sub>N<sub>2</sub>O<sub>3</sub> (554.94): C, 25.97; H, 1.82; N, 5.05. Found: C, 25.85; H, 1.91; N, 4.95.

**Experimental for antiprotozoal and antibacterial studies.** Experimental details concerning antiprotozoal and antimicrobial studies were described in literature [13, 19].

**Acknowledgments.** This study was supported by the Ministry of Science and Higher Education grant No. N209371439.

#### REFERENCES AND NOTES

- [1] Pagano, M. A.; Andrzejewska, M.; Ruzzene, M.; Sarno, S.; Cesaro, L.; Bain, J.; Elliott, M.; Meggio, F.; Kazimierczuk, Z.; Pinna, L. A. *J Med Chem* 2005, 7, 3049.
- [2] Pagano, M. A.; Bain, J.; Kazimierczuk, Z.; Sarno, S.; Ruzzene, M.; DiMaira, G.; Elliott, M.; Orzeszko, A.; Cozza, G.; Meggio, F.; Pinna, L. A. *Biochem J* 2008, 415, 353.
- [3] Gianoncelli, A.; Cozza, G.; Orzeszko, A.; Meggio, F.; Kazimierczuk, Z.; Pinna, L. A. *Bioorg Med Chem* 2009, 17, 7281.
- [4] Tamm, I. *J Exp Med* 1960, 111, 339.
- [5] Chang, J.; Nie, X.; Gudima, S.; Taylor, J. *J Virol* 2006, 80, 3205.
- [6] Biron, K. K.; Harvey, R. J.; Chamberlain, S. C.; Good, S. S.; Smith, A. A., III; Davies, M. G.; Talarico, C. L.; Miller, W. H.; Ferris, R. R.; Dornsife, E.; Stanat, S. C.; Drach, J. C.; Townsend, L. B.; Koszalka, G. W. *Antimicrob Agents Chemother* 2002, 46, 2365.
- [7] He, Y.; Wu, B.; Yang, J.; Robinson, D.; Risen, L.; Ranken, R.; Blyn, L.; Sheng, S.; Swayze, E. E. *Bioorg Med Chem Lett* 2003, 13, 3253.
- [8] Sharma, S.; Gangal, S.; Rauf, A. *Eur J Med Chem* 2009, 44, 1751.
- [9] Schmidt, J. *Paras Res* 1998, 84, 362.
- [10] Burton, D. E.; Lambie, A. J.; Ludgate, J. C.; Newbold, A.; Percival, A.; Sangers, D. T. *Nature (London)* 1965, 208, 1166.
- [11] Stefańska, J. Z.; Gralewska, R.; Starońskiak, B. J.; Kazimierczuk, Z. *Pharmazie* 1999, 54, 879.
- [12] Navarette-Vazquez, G.; Cedillo, R.; Hernandez-Campos, A.; Yopez, L.; Hernandez-Luis, F.; Valdez, J.; Morale, R.; Cortes, R.; Hernandez, M.; Cedillo, R. *Bioorg Med Chem Lett* 2001, 11, 187.
- [13] Andrzejewska, M.; Yopez-Mulia, L.; Cedillo-Rivera, R.; Tapia, A.; Vilpo, L.; Vilpo, J.; Kazimierczuk, Z. *Eur J Med Chem* 2002, 37, 973.
- [14] Kazimierczuk, Z.; Cottam, H. B.; Revankar, G. R.; Robins, R. K. *J Am Chem Soc* 1984, 106, 6379.
- [15] Burton, D. E.; Lambie, A. J.; Lane, D. W. J.; Newbold, G. T.; Percival, A. *J Chem Soc C* 1968, 1268.
- [16] Büchel, K-H. *Zeit Naturforsch* 1970, 25B, 934.
- [17] Baczynski, K.; Niementowski, S. *Chem Zentralbl* 1902, 73, 940.
- [18] Hoffer, M. *Chem Ber* 1960, 93, 2777.
- [19] Kazimierczuk, Z.; Chalimoniuk, M.; Laudy, A. E.; Moo-Puc, R.; Cedillo-Rivera, R.; Starońskiak, B. J.; Chrapusta, S. J. *Arch Pharm Res* 2010, 33, 821.